Výsledky vyhledávání - "Sirolimus/analogs

Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents:the SORT-OUT VII optical coherence tomography study

Autor: Lars Jakobsen, Evald Høj Christiansen, Jakob Hjort, Lars Romer Krusell, Christian Juhl Terkelsen, Lisette Okkels Jensen, Anne Kaltoft, Steen Dalby Kristensen, Jens Flensted Lassen, Karsten Tange Veien, Niels Ramsing Holm, Jouke Dijkstra, Morten Madsen, Hans Erik Bøtker, Michael Maeng, Ida R. Balleby, Lene Nyhus Andreasen, Knud Nørregaard Hansen

Publikováno v: Andreasen, L N, Holm, N R, Balleby, I R, Krusell, L R, Mæng, M, Jakobsen, L, Veien, K T, Hansen, K N, Kristensen, S D, Hjort, J, Kaltoft, A, Dijkstra, J, Terkelsen, C J, Lassen, J F, Madsen, M, Bøtker, H E, Jensen, L O & Christiansen, E H 2018, ' Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents : the SORT-OUT VII optical coherence tomography study ', European Heart Journal Cardiovascular Imaging, vol. 19, no. 3, pp. 329–338 . https://doi.org/10.1093/ehjci/jex035
Andreasen, L N, Holm, N R, Balleby, I R, Krusell, L R, Maeng, M, Jakobsen, L, Veien, K T, Hansen, K N, Kristensen, S D, Hjort, J, Kaltoft, A, Dijkstra, J, Terkelsen, C J, Lassen, J F, Madsen, M, Bøtker, H E, Jensen, L O & Christiansen, E H 2018, ' Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents : the SORT-OUT VII optical coherence tomography study ', European Heart Journal Cardiovascular Imaging, vol. 19, no. 3, pp. 329-338 . https://doi.org/10.1093/ehjci/jex035

Aims: To show non-inferiority of the 67- or 87 µm thick, sirolimus-eluting Orsiro drug eluting stent (DES) to the 122 µm thick, biolimus-eluting Nobori DES regarding size of vessel lumen outside the stent at 13-month follow-up.Methods and results:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfa6b1aa27b8460d13c50a2d628bc013
https://portal.findresearcher.sdu.dk/da/publications/e74fb794-744e-4482-8a15-f399e18dea87

Zobrazit plný text záznamu

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Publikováno v: Clinical Cancer Research, 22(19), 4797-4806. American Association for Cancer Research Inc.
Clinical Cancer Research, 22(19), 4797-4806
Clinical Cancer Research
Clinical cancer research, vol. 22, no. 19, pp. 4797-4806

Purpose: EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter. Experimental Design: Patients (n = 257) fulfilling eligibility

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d7fef0d1608d3697456d8fd4775b80
https://doi.org/10.1158/1078-0432.ccr-15-3153

Zobrazit plný text záznamu

Cellular and molecular effects of the mTOR inhibitor everolimus

Autor: Jean-François Dufour, Michelangelo Foti, Uttara Saran

Publikováno v: Clinical Science, Vol. 129, No 10 (2015) pp. 895-914
Clinical science (London England : 1979)

mTOR (mechanistic target of rapamycin) functions as the central regulator for cell proliferation, growth and survival. Up-regulation of proteins regulating mTOR, as well as its downstream targets, has been reported in various cancers. This has promot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ea83806fe28e4c63d6bb4013e0424f
https://doi.org/10.1042/cs20150149

Zobrazit plný text záznamu

Activation of the phosphatidylinositol 3′-kinase/AKT pathway in neuroblastoma and its regulation by thioredoxin 1

Autor: Hervé Sartelet, Anne-Laure Rougemont, Raouf Fetni, Monique Fabre, Stefan Michiels, Gilles Vassal, Mona Beaunoyer, Michel Duval, M. Castaing

Publikováno v: Human Pathology, Vol. 42, No 11 (2011) pp. 1727-39

Neuroblastoma is a malignant pediatric tumor with poor survival. The phosphatidylinositol 3'-kinase/AKT pathway is a crucial regulator of cellular processes including apoptosis. Thioredoxin 1, an inhibitor of tumor-suppressor phosphatase and tensin h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c477b084fefee17b0cbe011943c0673b
https://doi.org/10.1016/j.humpath.2011.01.019

Zobrazit plný text záznamu

New target therapies for patients with neuroendocrine tumors of the pancreas

Autor: Georgios Baltogiannis, Dimitrios H Roukos, Christos Katsios

Publikováno v: Expert Review of Gastroenterology & Hepatology. 5:563-566

Expert Rev Gastroenterol Hepatol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1677cd6e1e06cd01ec5a50785aae2f73
https://doi.org/10.1586/egh.11.55

Zobrazit plný text záznamu

Renal function three years after early conversion from a calcineurin inhibitor to everolimus:results from a randomized trial in kidney transplantation

Autor: D. Solbu, Claus Bistrup, Helene Andersson, Bengt Gustafsson, Jesper Melchior Hansen, Bengt von zur Mühlen, Lars Mjörnstedt, Bente Jespersen, Søren Schwartz Sørensen, Hallvard Holdaas

Publikováno v: Mjörnstedt, L, Schwartz Sørensen, S, von Zur Mühlen, B, Jespersen, B, Hansen, J M, Bistrup, C, Andersson, H, Gustafsson, B, Solbu, D & Holdaas, H 2015, ' Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation ', Transplant International, vol. 28, no. 1, pp. 42-51 . https://doi.org/10.1111/tri.12437
Mjörnstedt, L, Schwartz Sørensen, S, von Zur Mühlen, B, Jespersen, B, Hansen, J M, Bistrup, C, Andersson, H, Gustafsson, B, Solbu, D & Holdaas, H 2015, ' Renal function three years after early conversion from a calcineurin inhibitor to everolimus : results from a randomized trial in kidney transplantation ', Transplant international : official journal of the European Society for Organ Transplantation, vol. 28, no. 1, pp. 42-51 . https://doi.org/10.1111/tri.12437

Summary In a 36-month, open-label, multicenter trial, 202 kidney transplant recipients were randomized at week 7 post-transplant to convert to everolimus or remain on cyclosporine: 182 were analyzed to month 36 (92 everolimus, 90 controls). Mean (SD)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8013f8d6ab68fef9f774244b1d482f32
https://pure.au.dk/portal/da/publications/renal-function-three-years-after-early-conversion-from-a-calcineurin-inhibitor-to-everolimus(73c44c36-9b03-44c7-a2b7-17fbda919257).html

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání